DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
ADC Therapeutics (ADCT)
LOTIS-7 Phase 1b Update: ZYNLONTA + Glofitamab Combo Shows High CR Rate in DLBCL
Positive Catalyst — December 3, 2025 Update
NYSE: ADCT | ZYNLONTA (Loncastuximab Tesirine) | Target: 500M–1B USD Peak Revenue Potential
Executive Summary
ADC Therapeutics announced updated LOTIS-7 Phase 1b trial results on December 3, 2025, showing highly encouraging efficacy and manageable safety for ZYNLONTA + glofitamab combination in relapsed/refractory diffuse large B-cell lymphoma (DLBCL):
- Overall Response Rate (ORR): 89.8% (n=49 efficacy evaluable patients with ≥6 months follow-up)
- Complete Response (CR) Rate: 77.6% — with 33 of 38 CRs still durable as of data cutoff
- Safety Profile: Manageable; CRS rate 25% (all Grade 1–2) at approved 150 µg/kg dose
- Durability: Longest response >18 months; only 2 of 38 CR patients progressed
- Post-CAR-T Activity: 6 of 8 post-CAR-T patients achieved CR
Strategic Impact: The company believes this positions ZYNLONTA + glofitamab as a potential best-in-class bispecific combination in 2L+ DLBCL, complementing the ongoing Phase 3 LOTIS-5 trial (ZYNLONTA + rituximab).
Table of Contents
- 1. The December 3 Catalyst: LOTIS-7 Data Update
- 2. Company Overview & Leadership
- 3. ZYNLONTA: Mechanism, Approval & Market
- 4. LOTIS-7 Trial: Design, Efficacy & Safety
- 5. LOTIS-5 Phase 3 Trial: Path to 2L Approval
- 6. Financial Analysis (Q3 2025)
- 7. 12-Month Timeline & Key Events
- 8. Analyst Consensus & Price Targets
- 9. Trader Sentiment & Social Whispers
- 10. Upcoming Catalysts (2026–2027)
- 11. Key Risks
- 12. Valuation & Scenario Framework
- 13. Disclaimer
- 14. Sources, Tools & Support
1. The December 3 Catalyst: LOTIS-7 Updated Data
On December 3, 2025, ADC Therapeutics held a corporate update conference call to present updated Phase 1b data from the LOTIS-7 trial, evaluating ZYNLONTA (loncastuximab tesirine) in combination with Roche’s glofitamab (an Anti-CD20/CD3 bispecific T-cell engager) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
1.1 Key Efficacy Highlights (n=49, ≥6 Months Follow-Up)
Overall Response Rate
89.8%
Complete Response Rate
77.6%
Durable CRs
33 of 38
CRS Rate (150 µg/kg)
25%
| Population | ORR | CR Rate | Clinical Context |
|---|---|---|---|
| All Patients (n=49) | 89.8% | 77.6% | Median age 70; median 1 prior line; 16.3% post-CAR-T |
| Relapsed Patients (n=24) | 100% | 91.6% | Patients with initial response, then progression |
| Primary Refractory (n=25) | 80% | 64% | No response or progression ≤6 months after frontline |
| Post-CAR-T (n=8) | 75% | 75% (6/8 CR) | Heavily pretreated; difficult population |
1.2 Safety Profile: Manageable CRS & Neutropenia
Key Safety Observations
- Neutropenia: Most common Grade ≥3 AE (32.7%), consistent with each monotherapy label
- CRS at 150 µg/kg: 25% (all Grade 1–2); lower than glofitamab monotherapy (about 70% any-grade CRS in historical data)
- CRS at 120 µg/kg: 52% (1 case Grade 3); higher dose shows lower CRS, possibly via tumor debulking
- ICANS: Low rates; 1 case at 150 µg/kg (non-evaluable patient), 2 cases at 120 µg/kg (Grade 1–2, resolved)
- Grade 5 Events: 2 patients (4.1%); 1 non-treatment-related (sepsis from gastric ulcer), 1 treatment-related (cerebral edema more than 105 days post-last dose)
- Discontinuations: 6.1% both drugs; 12.2% ZYNLONTA only; 6.1% glofitamab only
Bottom Line: Safety profile is manageable and consistent with known toxicities of each agent. No new safety signals emerged. Lower CRS rates suggest ZYNLONTA’s tumor-debulking effect may mitigate bispecific-associated CRS.
Data note: Efficacy and safety figures in this section are taken from the company’s December 3, 2025 corporate update (press materials and call transcript) and are reported here for educational purposes.
2. Company Overview & Leadership
2.1 Company Profile
ADC Therapeutics SA is a commercial-stage biotechnology company focused on antibody-drug conjugates (ADCs) for hematological malignancies and solid tumors. The company’s lead approved product, ZYNLONTA, received FDA accelerated approval in April 2021 and European conditional approval for third-line+ large B-cell lymphoma.
| Metric | Value |
|---|---|
| Founded | 2012 (spin-out from Spirogen) |
| Headquarters | Lausanne, Switzerland |
| Public Listing | NYSE: ADCT (IPO May 2020) |
| Market Cap (Dec 3, 2025) | Approximately 494M USD (share price around 4.00–4.30 USD) |
| Employees | Approximately 337 (post-June 2025 restructuring; about 30% reduction) |
| Approved Product | ZYNLONTA (loncastuximab tesirine-lpyl) — Anti-CD19 ADC |
| Pipeline | PSMA-targeting ADC (IND-enabling activities targeted by end 2025); next-generation exatecan payload programs |
2.2 CEO & Management Team
Ameet Mallik, MBA — President & CEO
- Appointed: May 2022 (replaced cofounder Chris Martin)
- Background: Former Executive VP & Head of U.S. Oncology at Novartis; led commercial and medical operations across North America
- Prior Roles:
- Global Head of Marketing, Value & Access, Novartis Oncology
- Head of Latin America & Canada, Novartis Oncology
- CEO of Rafael Holdings (2021–2022)
- Associate Principal at McKinsey & Company
- Education: MBA from Northwestern University (Kellogg); Engineering degree from Cornell
- Assessment: Experienced commercial oncology leader with deep pharma/biotech expertise and broad exposure to global oncology markets.
Mohamed Zaki, M.D. — Chief Medical Officer
- Leads clinical development programs including LOTIS-7, LOTIS-5, and indolent lymphoma studies
- Responsible for regulatory strategy and FDA/EMA interactions
3. ZYNLONTA: Mechanism, Approval & Current Market
3.1 Mechanism of Action
ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate (ADC) consisting of:
- Humanized Anti-CD19 Monoclonal Antibody: Targets CD19 antigen expressed on B-cell malignancies
- Pyrrolobenzodiazepine (PBD) Dimer Payload: Highly potent DNA-crosslinking cytotoxic agent
- Cleavable Linker: Stable in circulation; cleaved inside target cells to release payload
Clinical Rationale: CD19 is widely expressed on B-cell lymphomas. The PBD payload induces irreversible DNA damage, leading to apoptosis. ZYNLONTA delivers targeted cytotoxicity with reduced systemic exposure versus traditional chemotherapy.
3.2 Current Approval & Label
| Regulatory Authority | Approval Date | Indication |
|---|---|---|
| FDA (U.S.) | April 2021 (Accelerated Approval) | Adult patients with r/r large B-cell lymphoma after ≥2 prior lines of systemic therapy (including DLBCL NOS, HGBL, DLBCL arising from FL) |
| European Commission | December 2022 (Conditional Approval) | Adult patients with r/r DLBCL and HGBL after ≥2 prior therapies |
| Health Canada | 2025 (Conditional Approval) | Third-line+ large B-cell lymphoma |
Note: FDA accelerated approval was granted based on single-arm Phase 2 LOTIS-2 trial data. Continued approval is contingent on verification of clinical benefit in the ongoing Phase 3 LOTIS-5 confirmatory trial.
3.3 Current Commercial Performance
Q3 2025 Net Product Revenue
15.8M USD
9M 2025 Net Product Revenue
Approximately 51M USD
Quarterly Run Rate (2-Year Avg)
15–18M USD
Estimated Market Share (3L+ DLBCL)
Approximately 5–10%
Current Positioning: ZYNLONTA competes in third-line+ DLBCL with bispecific monotherapies (glofitamab, epcoritamab, odronextamab), CAR-T therapies (axi-cel, liso-cel, tisa-cel), and other ADCs (polatuzumab vedotin). Management broadly frames the market split as approximately 60/40 between complex therapies (CAR-T, bispecifics) and more broadly accessible therapies (ADCs, monoclonals, chemo-based regimens).
4. LOTIS-7 Trial: Design, Efficacy & Safety Deep Dive
4.1 Trial Design & Rationale
Study Name: LOTIS-7 (Phase 1b dose-escalation and expansion)
Hypothesis: Combining ZYNLONTA (Anti-CD19 ADC) with glofitamab (Anti-CD20/CD3 bispecific) offers complementary mechanisms: ZYNLONTA delivers cytotoxic payload targeting CD19, while glofitamab engages T-cells to kill CD20+ B-cells. Sequential dosing (ZYNLONTA first) aims to debulk tumor and reduce CRS rates associated with bispecifics.
| Parameter | Details |
|---|---|
| Trial Phase | Phase 1b (Part 1: dose escalation; Part 2: dose expansion) |
| Population | Second-line+ large B-cell lymphoma (DLBCL, transformed FL, HGBL, Grade 3b FL) |
| Enrollment Target | Approximately 100 patients at 150 µg/kg ZYNLONTA dose (49 efficacy-evaluable with ≥6 months follow-up as of the update) |
| Dosing Schedule | Cycle 1: ZYNLONTA solo (tumor debulking); Cycles 2+: ZYNLONTA + glofitamab. ZYNLONTA up to 8 cycles; glofitamab up to 12 cycles |
| Primary Endpoint | Safety and tolerability |
| Secondary Endpoints | Efficacy (ORR, CR, DOR), PK, immunogenicity |
| Median Age | 70 years (range 26–85) |
| Median Prior Lines | 1 (range 1–5) |
| Post-CAR-T | 16.3% (8 patients) |
4.2 Updated Efficacy Results (December 3, 2025)
Best Overall Response Rate: 89.8%
- Complete Response (CR): 77.6% (38 of 49)
- Partial Response (PR): 12.2% (6 of 49)
- Stable Disease (SD): Approximately 6% (3 of 49)
- Progressive Disease (PD): Approximately 4% (2 of 49)
Durability of Response
- 33 of 38 CRs remained in CR as of the November 17 data cutoff
- Of the 5 CRs no longer in response: 2 progressed, 2 experienced Grade 5 AEs while still in CR, 1 was censored due to a secondary cancer requiring chemotherapy
- 14 patients converted from SD/PR to CR over time (depth of response improved with continued therapy)
- Longest response: longer than 18 months and ongoing
4.3 Subgroup Analysis: Relapsed vs Primary Refractory
| Population | N | ORR | CR Rate | Clinical Significance |
|---|---|---|---|---|
| Relapsed | 24 | 100% | 91.6% | Very strong activity in patients with initial response to frontline, then progression |
| Primary Refractory | 25 | 80% | 64% | Solid activity even in the most difficult-to-treat group (no response or progression within 6 months after frontline) |
Clinical Context: Primary refractory DLBCL patients have historically poor outcomes. A CR rate above 60% in this population is competitive versus other bispecific combinations and CAR-T data in similar settings.
4.4 Safety Summary
| Adverse Event | Any Grade | Grade ≥3 | Management |
|---|---|---|---|
| Neutropenia | Approximately 60% | 32.7% | Consistent with ZYNLONTA/glofitamab monotherapy labels; G-CSF support |
| CRS (150 µg/kg) | 25% | 0% | All Grade 1–2; tocilizumab, steroids, antipyretics, fluids |
| CRS (120 µg/kg) | 52% | 2% (1 patient) | Grade 3 case: ICU admission, tocilizumab, dexamethasone, vasopressors |
| ICANS | Approximately 2% | 0% | Grade 1–2; resolved with steroids |
| Thrombocytopenia | Approximately 40% | Approximately 10% | Platelet transfusions as needed |
| Anemia | Approximately 35% | Approximately 8% | RBC transfusions as needed |
| Grade 5 AEs | — | 4.1% (2 patients) | 1 non-treatment-related (sepsis from GI ulcer); 1 treatment-related (cerebral edema long after last dose) |
Key Safety Takeaway
The combination safety profile appears manageable and consistent with known toxicities of each agent separately. The lower CRS rate at 150 µg/kg (25%) versus historical data for glofitamab alone supports the tumor-debulking hypothesis, though this remains an interpretation rather than a proven mechanism.
5. LOTIS-5 Phase 3 Trial: Path to Second-Line Approval
LOTIS-5 is the pivotal Phase 3 confirmatory trial designed to verify clinical benefit of ZYNLONTA in combination with rituximab versus rituximab + gemcitabine/oxaliplatin (R-GemOx) in second-line+ DLBCL. Success in this trial would convert ZYNLONTA’s accelerated approval to full approval and expand the label into the second-line setting.
5.1 Trial Design
| Parameter | Details |
|---|---|
| Phase | Phase 3 (randomized, open-label) |
| Arms | Arm A: ZYNLONTA + rituximab | Arm B: R-GemOx (standard of care) |
| Enrollment | Approximately 340 patients (second-line+ r/r DLBCL) |
| Primary Endpoint | Progression-free survival (PFS) by independent review |
| Key Secondary Endpoints | Overall survival (OS), ORR, CR rate, duration of response, safety |
| Status | Fully enrolled; awaiting prespecified number of PFS events |
| Expected Topline Data | First half of 2026 (company guidance) |
5.2 Regulatory Path Post-LOTIS-5
Assuming positive LOTIS-5 results (company outline):
- H1 2026: Topline PFS data announced
- H2 2026: Supplemental BLA submission to FDA; potential MAA submission to EMA
- H1 2027: Possible FDA/EMA approvals for second-line+ DLBCL; NCCN compendia inclusion; publication in a peer-reviewed journal
- 2027 onwards: Commercial ramp-up in second-line; larger addressable market versus third-line-only positioning
6. Financial Analysis (Q3 2025 Snapshot)
6.1 Income Statement (Q3 2025 vs Q3 2024)
| Metric (USD M) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | 16.4 | 18.5 | 58.3 | 47.9 |
| Net Product Revenue | 15.8 | 18.0 | 51.2 | 42.2 |
| License Revenue & Royalties | 0.7 | 0.4 | 7.1 | 5.7 |
| R&D Expense | 28.9 | 32.0 | 90.2 | 88.8 |
| G&A Expense | 8.3 | 9.9 | 27.1 | 30.9 |
| Restructuring Costs | 0.4 | 0.0 | 13.5 | 0.0 |
| Total Operating Expenses | 47.4 | 49.8 | 163.0 | 142.4 |
| Net Loss (GAAP) | (41.0) | (43.6) | (136.2) | (120.6) |
| Adjusted Net Loss | (22.5) | (24.1) | (78.2) | (72.8) |
| GAAP EPS | (0.30) | (0.55) | (1.14) | (1.93) |
| Adjusted EPS | (0.19) | (0.28) | (0.66) | (0.93) |
6.2 Balance Sheet (September 30, 2025)
Cash & Cash Equivalents
234.7M USD
Pro Forma Cash (Post-October PIPE)
Approximately 292M USD
Deferred Royalty Obligation
340.2M USD
Stockholders’ Equity (Deficit)
(238.2M USD)
| Balance Sheet Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
| Total Assets | 376.8M USD | 393.6M USD |
| Total Liabilities | 615.0M USD | 556.8M USD |
| Senior Secured Term Loans | 115.2M USD | 105.6M USD |
| Deferred Royalty Obligation | 340.2M USD | 301.0M USD |
| Stockholders’ Equity | (238.2M USD) | (163.2M USD) |
6.3 Capital Raises & Cash Runway
2025 Financing Activity (Overview)
- June 2025 PIPE: 100M USD gross (approximately 93.1M USD net)
- October 2025 PIPE: 60M USD gross (approximately 57.6M USD net)
- Pro Forma Cash: About 292M USD after the October deal
- Runway: Company expects cash to fund operations into 2028 at the current adjusted operating expense run rate (around 45M USD per quarter)
Interpretation: The balance sheet gives ADC Therapeutics room to reach key readouts (LOTIS-5 and LOTIS-7) without an immediate need for additional capital, assuming no major negative surprises.
6.4 June 2025 Restructuring
In June 2025, the company executed an approximate 30% headcount reduction and initiated the shutdown of its UK manufacturing facility. This resulted in about 13.5M USD of restructuring charges but is expected to generate more than 20M USD in annual operating expense savings going forward. Management framed this as a way to prioritize ZYNLONTA’s highest-value opportunities (LOTIS-5, LOTIS-7) and extend cash runway.
Financial data note: Numbers in this section are taken from management commentary and the Q3 2025 filings. They are presented here in summarized form and may be rounded for readability.
7. 12-Month Timeline & Key Events
March 2025
FY 2024 10-K Filed: Company reports 66.7M USD FY 2024 net product revenue. LOTIS-5 enrollment completed. Stock trades broadly in the 1.50–2.50 USD range.
June 2025
100M USD PIPE Financing: Capital raise to fund LOTIS trials and extend runway. Workforce reduction of about 30% announced in parallel. Stock rallies into the 3.50–4.00 USD area.
August 2025
Q2 Earnings & EHA Update: Net product revenue of 18.1M USD. Early LOTIS-7 data indicate high ORR and CR rates (smaller initial cohort). Stock reaches the 4.50–4.80 USD region.
September–October 2025
LOTIS-7 Enrollment Acceleration: Company reports improved enrollment and activation of additional trial sites.
October 27, 2025
60M USD PIPE #2: Second financing at around 4.00 USD per share raises 60M USD gross. Pro forma cash moves close to 292M USD.
November 2025
Q3 Earnings: Net product revenue declines to 15.8M USD (from 18.0M USD Q3 2024) due to ordering variability and competitive dynamics. Stock trades roughly in the 3.90–4.20 USD range.
December 3, 2025
LOTIS-7 Updated Data: 49 patients with at least six months of follow-up show 89.8% ORR and 77.6% CR rate with manageable safety. Stock reacts positively on the day.
8. Analyst Consensus & Price Targets
8.1 Current Consensus (December 2025)
| Metric | Value |
|---|---|
| Number of Analysts | Approximately 5–6 covering the stock |
| Consensus Rating | Buy / Strong Buy |
| Average Price Target | 7.50–8.00 USD |
| Target Range | Low: 5.00 USD | High: 10.00 USD |
| Implied Upside (from 4.00 USD) | Roughly +88% to +150% |
8.2 Recent Analyst Actions (Illustrative)
| Date | Analyst/Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| Aug 13, 2025 | Guggenheim | Reiterate | Strong Buy | 10.00 USD |
| Oct 16, 2025 | H.C. Wainwright | Target Revision | Buy | 8.00 → 7.00 USD |
| Jun 20, 2025 | RBC Capital | Downgrade | Outperform → Buy | 8.00 → 5.00 USD |
| Mar 7, 2025 | Cantor Fitzgerald | Reiterate | Overweight | Not disclosed |
8.3 Bull vs Bear Analyst Views (Framework)
Bull Case (Analyst Perspective)
- LOTIS-7 combination data position ZYNLONTA as a potentially strong bispecific partner in 2L+ DLBCL.
- LOTIS-5 success could unlock a 500–800M USD peak revenue opportunity in DLBCL alone.
- Indolent lymphoma expansion could add another 100–200M USD.
- Pro forma cash of roughly 292M USD provides runway through multiple catalysts.
- Valuation multiples appear discounted versus commercial-stage oncology peers.
Bear Case (Analyst Perspective)
- Third-line ZYNLONTA revenues show pressure; competition from bispecifics and CAR-T remains intense.
- LOTIS-5 is a binary pivotal trial; a miss would be highly damaging for the franchise.
- LOTIS-7 remains early-stage (Phase 1b); the regulatory path for the combo is not yet defined.
- Balance sheet carries meaningful debt and royalty obligations; equity is negative.
- Restructuring may signal commercial execution challenges.
9. Trader Sentiment & Social Whispers
Social Media Sentiment Box — Unverified Commentary
Important: The following are unverified trader opinions and comments circulating on public forums (Twitter/X, StockTwits, Reddit) as of early December 2025. They are included only to illustrate market sentiment and should not be used as a basis for investment decisions.
“The December 3 data update looks strong. A near 78% CR rate in 2L+ DLBCL with manageable CRS compares well with other bispecific combinations. I am holding through the LOTIS-5 readout in the first half of 2026.”
“The stock has traded sideways for a long time in the 2–4 USD range. LOTIS-7 is interesting but still early. Until LOTIS-5 reads out, I do not see a clear reason to commit significant capital.”
“Relapsed patients showed a much higher CR rate than primary refractory. Baseline mix in LOTIS-5 will matter a lot for the headline results.”
“Two PIPE deals in 2025 are dilutive, but they also extend the runway. It is a high-risk, high-reward setup typical for this part of the biotech cycle.”
Overall informal sentiment (0–10 scale, 10 = very bullish): around 6.5/10, with cautious optimism offset by the binary nature of LOTIS-5 and the company’s balance sheet profile.
10. Upcoming Catalysts (2026–2027)
Major Anticipated Catalysts
- H1 2026: LOTIS-5 Phase 3 topline PFS data.
- H1 2026: LOTIS-7 enrollment completion at the selected 150 µg/kg dose.
- End 2025 / Early 2026: IND-enabling activities for the PSMA-targeting ADC.
- Late 2026: Potential full LOTIS-7 data presentation and manuscript submission.
- H2 2026: Possible LOTIS-5 regulatory filings (FDA/EMA) if data are supportive.
- 2027: Potential approvals and commercial expansion in second-line DLBCL if LOTIS-5 succeeds.
Peak Revenue Opportunity (Management Framing)
| Indication / Program | Peak Revenue Potential (U.S.) |
|---|---|
| LOTIS-7 (ZYNLONTA + glofitamab, 2L+ DLBCL) | 300–500M USD (assuming strong data and compendia support) |
| LOTIS-5 (ZYNLONTA + rituximab, 2L+ DLBCL) | 200–300M USD (broader accessibility vs high-complexity therapies) |
| Combined DLBCL Opportunity | 500–800M USD |
| Indolent Lymphomas (FL, MZL) | 100–200M USD (exploratory) |
| Total Potential ZYNLONTA Peak Revenue | 600M–1.0B USD |
11. Key Risks
11.1 Clinical and Regulatory Risks
- LOTIS-5 Outcome: A negative or ambiguous PFS result could lead to withdrawal of accelerated approval in the United States.
- LOTIS-7 Path: Phase 1b data are encouraging but not registrational; regulators may require larger randomized trials before any label changes.
- Competitive Pressure: CAR-T therapies and bispecific antibodies are rapidly evolving, potentially compressing the addressable population.
- Long-Term Safety: Any new serious adverse events emerging with longer follow-up or in broader use could challenge the benefit-risk profile.
11.2 Commercial Risks
- Revenue Volatility: The decline in Q3 2025 revenue vs Q3 2024 suggests competitive and ordering dynamics that can be hard to predict.
- Execution: Workforce reductions may help costs but can also reduce commercial reach and field presence.
- Payer Dynamics: High prices for advanced oncology drugs may limit uptake depending on payer and guideline positions.
11.3 Financial Risks
- Negative Equity: The company shows a substantial accumulated deficit and negative stockholders’ equity position.
- Obligations: Deferred royalty obligations and term loans create fixed financial burdens.
- Dilution: Past PIPE financings have already expanded the share count; further raises could be required in less favorable scenarios.
12. Valuation & Scenario Framework
Bull Case
10 – 15 USD
Assumptions: LOTIS-5 meets the primary endpoint with convincing PFS benefit; LOTIS-7 supports strong usage and compendia backing; ZYNLONTA reaches 400–600M USD total peak revenue; the market applies 2–3x sales multiple.
Base Case
6 – 9 USD
Assumptions: LOTIS-5 delivers clinically relevant but not transformational data; LOTIS-7 is adopted but remains more niche; ZYNLONTA reaches 250–400M USD peak revenue; valuation settles around 1–1.5x sales.
Bear Case
1 – 3 USD
Assumptions: LOTIS-5 fails or is inconclusive; U.S. approval becomes challenged; ZYNLONTA revenues fall sharply; equity value reflects a distressed or asset-sale scenario.
Valuation Approach
| Scenario | Illustrative Probability | Peak Revenue | Sales Multiple | Indicative Equity Value |
|---|---|---|---|---|
| Bull (LOTIS-5 and LOTIS-7 strong) | 30% | 600M USD | 2.5× | Approximately 1.5B USD (around 12 USD/share) |
| Base (LOTIS-5 moderate success) | 40% | 300M USD | 1.5× | Approximately 450M USD (around 3.6 USD/share) |
| Bear (LOTIS-5 failure) | 20% | 50M USD | 0.5× | Approximately 25M USD (around 0.2 USD/share) |
| Liquidation / Asset Sale | 10% | — | — | Approximately 150M USD (around 1.2 USD/share) |
| Blended Indicative Value (framework only, not a target) | Approximately 5.5–7.0 USD/share | |||
Important: These are illustrative scenario ranges for educational purposes, not price targets or recommendations.
13. Disclaimer
Important Disclaimer
This report is intended solely for informational and educational purposes. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security, including ADC Therapeutics (ADCT).
- High Risk: Biotech equities, especially companies dependent on a small number of clinical programs, carry a high risk of capital loss, including total loss.
- Data Sources: Figures and timelines are based on company communications, public filings, and third-party sources available at the time of drafting. While care is taken to summarize accurately, errors or omissions are always possible.
- Dynamic Information: Clinical data, regulatory positions, and financial conditions can change quickly. Readers should always verify current information independently.
- No Personalization: This report does not take into account any individual reader’s financial situation, risk tolerance, or objectives. For any investment decision, consult a licensed financial professional.
- Sentiment and Social Commentary: Any mention of trader opinions, social media comments, or forum posts reflects unverified anecdotal sentiment, not facts.
Bottom line: treat this as a study case and a structured way to think about clinical and financial risk, not as a signal to open, close, or adjust positions.
14. Sources, Tools, Affiliates & Support
Key Public Sources (to double-check and go deeper)
- ADC Therapeutics Investor Relations — earnings releases, corporate presentations and LOTIS program updates.
- SEC EDGAR — 10-Q and 10-K filings for ADC Therapeutics.
- ClinicalTrials.gov — protocol and status for LOTIS-5 and LOTIS-7.
Tools for Further Research (Affiliate Links)
- Detailed charts and fundamentals on Finviz Open ADCT page on Finviz (affiliate)
- Earnings call transcripts, models and community articles on Seeking Alpha Seeking Alpha coverage (referral link)
If you find this kind of structured biotech work useful and want to help keep the Merlintrader trading Blog free for everyone, you can support the project with a small donation via PayPal.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
